US › Healthcare

Werewolf Therapeutics Inc (HOWL)

US · Healthcare · Biotechnology

$0.98-1.71%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$21.0M

Net profit

$3.7M

EPS

$0.08

EPS estimate

$-0.28

Net margin

17.5%

EPS came in at 0.08 against a street estimate of -0.28 — a beat of 128.6%.

Key statistics

Market cap

$48.5M

Forward P/E

0.0

P/B

2.95

Book value

$0.34

EPS (TTM)

$-0.73

52-week high

$1.83

52-week low

$0.27

50-day MA

$0.82

200-day MA

$0.66

Beta

0.51

Analyst view

with an average price target of $7.00.

Shareholding

Insiders

6.62%

Institutions

39.11%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	4.91%
Balyasny Asset Management LLC	3.68%
Vanguard Capital Management, LLC	2.51%
Renaissance Technologies Corp	1.39%
Lynx1 Capital Management, LP	1.35%
Sphera Funds Management Ltd.	1.29%
DC Funds, LP	1.21%
Verdad Advisers, LP	0.72%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Werewolf Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.